Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells

Molecular Cancer Therapeutics

Volumn 4, Issue 11, 2005, Pages 1699-1709

  Uemura, Hiroji ^a   Ishiguro, Hitoshi ^a   Nagashima, Yoji ^a   Sasaki, Takeshi ^b   Nakaigawa, Noboru ^a   Hasumi, Hisashi ^a   Kato, Shingo ^a   Kubota, Yoshinobu ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 6; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CULTURE; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DRUG MECHANISM; EPITHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; STROMA CELL; TUMOR GROWTH; XENOGRAFT;

ANGIOTENSIN II; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; CYTOKINES; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERLEUKIN-6; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MICROCIRCULATION; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTORS, ANGIOTENSIN; STROMAL CELLS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28044466650     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0295     Document Type: Article

References (40)

1. The Research Group for Population-Based Cancer Registration in Japan. Cancer incidence in Japan. In: Tajima K, Kuroishi T, Oshima A, editors. Cancer mortality and morbidity statistics. Monograph on cancer research. No. 51. Tokyo: Japan Scientific Societies Press, Karger; 2004. p. 95-9.
2. Ishiguro H, Uemura H, Fujinami K, Ikeda N, Ohta S, Kubota Y. 55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor. Int J Cancer 2003;105:26-32.
3. Fujinami K, Uemura H, Ishiguro H, Kubota Y. Liprin-α2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is down-regulated by androgens in the human prostate cancer cell line LNCaP. Int J Mol Med 2002;10:173-6.
4. Hasumi H, Ishiguro H, Nakamura M, et al. Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival. Int J Cancer 2005;115:911-6.
5. Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 2004;60:178-6.
6. Sivashanmugam P, Tang L, Daaka Y. Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells. J Biol Chem 2004;279:21154-9.
7. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000;42: 150-60.
8. 1 receptor. Nature 1995;375: 247-50.
9. McWhinney CD, Hunt RA, Conrad KM, Dostal DE, Baker KM. The type I angiotensin II receptor couples to Stat1 and Stat3 activation through Jak2 kinase in neonatal rat cardiac myocytes. J Mol Cell Cardiol 1997;29: 2513-24.
10. Fujiyama S, Matsubara H, Nozawa Y, et al. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001;88:22-9.
11. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 2001;495:197-200.
12. Inwang ER, Puddefoot JR, Brown CL, et al. Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer 1997;75: 1279-83.
13. Uemura H, Ishiguro H, Nakaigawa N, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003;2:1139-47.
14. Lin J, Freeman MR. Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells. Prostate 2003; 54:1-7.
15. Mikata K, Uemura H, Ohuchi H, Ohta S, Nagashima Y, Kubota Y. Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: gene therapy by electroporation. Mol Cancer Ther 2002;1: 247-52.
16. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352: 179-84.
17. Bok RA, Halabi S, Fei DT, et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001;61:2533-6.
18. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127-33.
19. Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;7:1738-44.
20. Scher HI, Sarkis A, Reuter V, et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms. Clin Cancer Res 1995;5:545-50.
21. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 2003;100: 2645-50.
22. Keane MP, Belperio JA, Moore TA, et al. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999;162:5511-8.
23. Lee LF, Louie MC, Desai SJ, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004;23:2197-205.
24. Ohta M, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol 2003; 22:773-8.
25. 1 receptor-mediated vasopressin release and drinking are potentiated by AT2 receptor antagonist. Eur J Pharmacol 1995;275:277-82.
26. Takeda H, Katagata Y, Hozumi Y, Kondo S. Effects of angiotensin II receptor signaling during skin wound healing. Am J Pathol 2004;165: 1653-62.
27. Kue PF, Daaka Y. Essential role for G proteins in prostate cancer cell growth and signaling. J Urol 2000;164:2162-7.
28. Raj GV, Barki-Harrington L, Kue PF, Daaka Y. Guanosine phosphate binding protein coupled receptors in prostate cancer: a review. J Urol 2002;167:1458-63.
29. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002;8: 2912-23.
30. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 2002;62: 3298-307.
31. Song QH, Klepeis VE, Nugent MA, Trinkaus-Randall V. TGF-β1 regulates TGF-β1 and FGF-2 mRNA expression during fibroblast wound healing. Mol Pathol 2002;55:164-76.
32. Barrett-Lee P, Travers M, Luqmani Y, Coombes RC. Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br J Cancer 1990;61:612-7.
33. Coffey RJ, Shipley GD, Moses HL. Production of transforming growth factors by human colon cancer lines. Cancer Res 1986;46:1164-9.
34. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998;37:19-29.
35. Miyajima A, Kosaka T, Asano T, et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002;62:4176-9.
36. O'Mahony OA, Djahanbahkch O, Mahmood T, Puddefoot JR, Vinson GP. Angiotensin II in human seminal fluid. Hum Reprod 2000; 15:1345-9.
37. Fraser LR, Osiguwa OO. Human sperm responses to calcitonin, angiotensin II and fertilization-promoting peptide in prepared semen samples from normal donors and infertility patients. Hum Reprod 2004; 19:596-606.
38. Fraser LR, Pondel MD, Vinson GP. Calcitonin, angiotensin II and FPP significantly modulate mouse sperm function. Mol Hum Reprod 2001;7: 245-53.
39. O'Mahony OA, Barker S, Puddefoot JR, Vinson GP. Synthesis and secretion of angiotensin II by the prostate gland in vitro. Endocrinology 2004;146:392-8.
40. Uemura H, Nakaigawa N, Ishiguro H, Kubota Y. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets 2005;5:307-23.